A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...
OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative ...
A phase Ib/II trial testing famitinib added to dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast ...
Anti-angiogenic inhibitors (AI) have transformed cancer treatment but are associated with vascular toxicities. The specific association with peripheral artery aneurysm and dissection (PAAD) remains ...
Universidad Nacional Autonoma de Mexico and Vian Therapeutics Inc. have synthesized peptides acting as angiogenesis inhibitors reported to be useful for the treatment of cancer, diabetic retinopathy ...
S-acylation switches the fate of a plant peptide precursor in cell wall damage responses To exclude nonspecific thiol-reactive agents as well as possible molecules targeting the FAD binding pocket in ...
Recent findings have identified nucleolin as a key factor in the nuclear transport of endostatin within endothelial cells. Endostatin, known for its role as a potent inhibitor of angiogenesis, has ...
Angiogenesis inhibitors showed no increased risk of arterial dissections or aneurysms in metastatic colorectal cancer patients. The study involved 34,733 patients, with 195 cases matched to 1950 ...
The analysis revealed that AI treatment significantly increased the incidence of hypertension (relative risk [RR], 3.28 [95% CI, 2.82–4.30]), myocardial ischemia or infarction events (RR, 2.09 [95% CI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results